Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

NASDAQ:AGRX opened at $0.21 on Friday. Agile Therapeutics has a 52 week low of $0.18 and a 52 week high of $11.40. The firm has a market capitalization of $8.53 million, a PE ratio of -0.01 and a beta of 1.13. The stock has a 50 day moving average of $0.26 and a 200-day moving average of $0.26.

Institutional Investors Weigh In On Agile Therapeutics

A number of hedge funds have recently bought and sold shares of AGRX. BlackRock Inc. boosted its stake in Agile Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock valued at $319,000 after acquiring an additional 16,104 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 281.3% in the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares during the period. Virtu Financial LLC bought a new stake in shares of Agile Therapeutics during the 4th quarter worth approximately $32,000. Finally, Jane Street Group LLC acquired a new position in Agile Therapeutics during the 2nd quarter worth approximately $108,000. 5.70% of the stock is currently owned by institutional investors.

About Agile Therapeutics

(Get Rating)

Agile Therapeutics, Inc is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.